News & Events

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis. This charge primarily relates to premium on equity securiti…

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2025 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $83 million on a pre-tax basis. This charge primarily relates to the previously disclosed $8…

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2024 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis. This charge relates to development milestone and up-front pa…

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the second quarter 2024 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $24 million on a pre-tax basis. This charge relates to up-front payments, as well as a prem…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 26, 2024, based on a previously disclosed Chief Financial Officer succession plan, Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer to succeed the current Chief Financi…

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of $100 million on a pre-tax basis. This charge relates to a development milestone payment that became due up…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company. Dr. Tessier-Lavigne informed Regeneron that his decision to retire was due to potential conflicts that may arise as he…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 14 , 2023, P. Roy Vagelos, M.D., Chair of the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”), notified Regeneron of his decision not to stand for re-election at the 2023 Annual Meeting of Shareholders to be held on June 9, 2023 (the “ 2023 Annual Meeting ”). Dr. Vagelos will continu…

Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis, primarily relating to an up-front payment in connection with…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2022, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Craig B. Thompson, M.D. as a director. With the addition of Dr. Thompson, the Board has been expanded from 12 to 13 members. Dr. Thompson has also been appointed to serve on the Technology Committee of the Board. In accordance wit…

Entry into a Material Definitive Agreement. A&R IO License and Collaboration Agreement . On June 1, 2022, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), and Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“ Sanofi Biotechnology ”), entered into the Amended and Restated Immuno-Oncology License and Collaboration Agreement (the “ A&R IO LCA ”), which amends the Immuno-Oncology License and Collaboration Agr…

Entry into a Material Definitive Agreement. On September 14, 2021, Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) entered into a modified Statement of Work (the “ Amendment ”) under the supply agreement (the “ Supply Agreement ” (previously filed as Exhibit 10.1 to Regeneron’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021)) with the Army Contracting Command, New Jersey, an entity acting on behalf of the U.S. Department of Defense and the U.S.…